Clinical trials: Migraine
Preventive Treatment of Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine attacks in adults and for the preventive treatment of episodic migraine in adults when administered every…
- Trial name
- NCT07729462
- Testing
- Rimegepant
- Where
- 21 sites in United States, Israel
- Volunteers
- 400 people
- Sponsor
- Pfizer
Migraine
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep, as compared with placebo, in the treatment of moderate or severe of migraine.
- Trial name
- NCT07816367
- Testing
- Elismetrep
- Where
- 72 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Kallyope Inc.
Chronic Migraine
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other…
- Trial name
- NCT06810505
- Testing
- Atogepant
- Where
- 66 sites in United States, Canada and 9 more
- Volunteers
- 420 people
- Sponsor
- AbbVie
Migraine
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it.
- Trial name
- NCT07646613
- Testing
- ASY202
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Aspeya, Inc.
Episodic Migraine
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- NCT05711394
- Testing
- Atogepant
- Where
- 98 sites in United States, Belgium and 14 more
- Volunteers
- 450 people
- Sponsor
- AbbVie
Migraine
Study of EVO756 in Adults With Migraine
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
- Trial name
- NCT07616128
- Testing
- EVO756, Dose 1, EVO756, Dose 2
- Where
- 35 sites in United States, Canada and 1 more
- Volunteers
- 330 people
- Sponsor
- Evommune, Inc.
Migraine, Chronic Migraine
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again.
- Trial name
- NCT06428838
- Testing
- Eptinezumab, Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Dr George Medvedev
Acute Treatment of Migraine
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine.
- Trial name
- NCT06995729
- Testing
- Zavegepant
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Migraine Disorders
MMA Embolization for Refractory Chronic Migraine
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic…
- Trial name
- MIGRAINE (NCT06735833)
- Testing
- Middle Meningeal Artery embolization
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Migraine With or Without Aura
A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea
The purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic…
- Trial name
- Rimegepant PMS (NCT07497854)
- Testing
- Rimegepant sulfate
- Volunteers
- 3,000 people
- Sponsor
- Pfizer
Migraine, With or Without Aura
Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults
The purpose of this study is to evaluate the long-term safety of BR005-036C tablets in the acute treatment of migraines
- Trial name
- NCT07835152
- Testing
- BR005-036C
- Where
- 81 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.
Migraine, Fibromyalgia
The Effect of Remote Electrical Neuromodulation (REN) on Conditioned Pain Modulation (CPM) in Migraine and Fibromyalgia
Migraine and Fibromyalgia (FM) are chronic pain disorders characterized by altered central pain processing and impaired endogenous pain inhibition.
- Conditions
- Migraine, Fibromyalgia, Conditioned Pain Modulation
- Trial name
- NCT07841509
- Testing
- Remote Electrical Neuromodulation (REN) device
- Where
- 2 sites in United States, Israel
- Volunteers
- 120 people
- Sponsor
- Theranica
Migraine Disorders, Chronic Migraine Headache
EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine
EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine…
- Conditions
- Migraine Disorders, Chronic Migraine Headache, Migraine
- Trial name
- EMBRACE-OBS (NCT07652034)
- Testing
- Middle Meningeal Artery Embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cortex Neurovascular
Migraine
Consistency of Response With Rimegepant in Acute Treatment of Migraine
This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks.
- Trial name
- CORRELATE-UK (NCT06898047)
- Testing
- Rimegepant for acute migraine treatment
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Pfizer
Migraine, Migraine With Aura
A Comprehensive Digital Care Program for Migraine Management
This study evaluates the clinical effectiveness of the Enso for Migraine program, a comprehensive digital care program combining an FDA-cleared neuromodulation wearable device (Enso), personalized exercise therapy, and a…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT07642414
- Testing
- Neuromodulation Wearable Device, Migraine Digital Care Program
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Hinge Health, Inc
Chronic Migraine Headache
Clinical Exploration of NEUROMARK System in Participants With Chronic Migraine
Clinical exploration of NEUROMARK System in Participants with Chronic Migraine
- Trial name
- NCT06862674
- Testing
- NEUROMARK System
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Neurent Medical
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Migraine
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to light, sensitivity to sound, nausea, or other symptoms.
- Trial name
- ATO ACUTE (NCT06241313)
- Testing
- Atogepant
- Where
- 149 sites in Belgium, China and 13 more
- Volunteers
- 2,158 people
- Sponsor
- AbbVie
Migraine
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies…
- Trial name
- NCT06701526
- Testing
- Eptinezumab
- Where
- 21 sites in United States
- Volunteers
- 164 people
- Sponsor
- H. Lundbeck A/S
Episodic Migraine, Chronic Migraine
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound.
- Trial name
- MERANTI (NCT06625060)
- Testing
- Corabotase, Corabotase dose A, Corabotase dose B
- Where
- 162 sites in United States, Australia and 12 more
- Volunteers
- 670 people
- Sponsor
- Ipsen